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Abstract
Once thought to be a part of the ‘dark matter’ of the genome, long non-coding RNAs (lncRNAs) are emerging as an integral
functional component of the mammalian transcriptome. LncRNAs are a novel class of mRNA-like transcripts which, despite
no known protein-coding potential, demonstrate a wide range of structural and functional roles in cellular biology.
However, the magnitude of the contribution of lncRNA expression to normal human tissues and cancers has not been
investigated in a comprehensive manner. In this study, we compiled 272 human serial analysis of gene expression (SAGE)
libraries to delineate lncRNA transcription patterns across a broad spectrum of normal human tissues and cancers. Using a
novel lncRNA discovery pipeline we parsed over 24 million SAGE tags and report lncRNA expression profiles across a panel
of 26 different normal human tissues and 19 human cancers. Our findings show extensive, tissue-specific lncRNA expression
in normal tissues and highly aberrant lncRNA expression in human cancers. Here, we present a first generation atlas for
lncRNA profiling in cancer.
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Introduction
Genome instability and mutation are a hallmark of cancer [1].
Genetic and epigenetic changes result in aberrant expression of
protein-coding genes and many classes of non-coding RNAs
(ncRNAs), including microRNAs (miRNAs). MiRNAs have
proven to be major players in human carcinogenesis, despite
comprising only a small fraction of ncRNAs [2].
Once thought to be the ‘dark matter’ of the genome, ncRNAs
have emerged as an integral component of the mammalian
transcriptome [3,4,5]. These enigmatic molecules are defined by
lack of protein-coding sequence, yet can play both structural and
functional roles in the cell [6,7]. NcRNAs can been grouped into
two major classes, the small ncRNAs, which include miRNAs and
other non-coding transcripts of less than 200 nucleotides (nt), and
the more recently described lncRNAs, which range from 200 nt to
.100 kilobases (kb) [8].
LncRNAs can be intergenic, intronic, antisense or overlapping
with protein-coding genes or other ncRNAs [9,10,11,12]. The
known repertoire of lncRNA functions is rapidly expanding – with
demonstrated roles as mediators of mRNA decay [13], structural
scaffolds for nuclear substructures [14,15], as host genes for
miRNAs [16,17], and as regulators of chromatin remodeling
[18,19,20,21] – even though the functional identities of many
lncRNAs have yet to be uncovered [6,7,22]. Recently, human
cancers have been described to have altered expression of satellite
repeats [23], transcribed ultra conserved regions (T-UCRs) [24],
and antisense transcripts [25]. Beyond expression changes,
accumulating evidence indicates aberrant expression of lncRNAs
may play an important functional role in cancer biology
[26,27,28]. The well-studied HOX antisense intergenic RNA
(HOTAIR), for example, is highly expressed in breast cancers and
breast cancer metastases and plays a role in retargeting chromatin
remodeling complexes [29]. Similarly, high expression of the
nuclear speckle associated lncRNA metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1) modulates alternative
splicing and has been associated with metastasis and poor outcome
in patients with lung cancer [30,31]. While these examples are
intriguing, the extent of the contribution of differential lncRNA
expression to human cancer is currently unknown.
With a conservative estimate of 23,000 lncRNAs in the human
genome, these transcripts rival the ,20,000 protein-coding genes
[5,11,32,33]. Over the past two decades, microarray profiling has
generated a wealth of information on protein-coding gene expression
patterns in human cancers. However, as lncRNA specific probes are
underrepresented on commercial microarrays used in cancer tran-
scriptome profiling, these data do not apply to ncRNAs. Global
sequencing of RNA populations is a new approach used to profile RNA
expression levels that will capture the extent of lncRNA expression.
Recently, genome-wide ncRNA expression profiles were determined in
11 samples representing different types of human tissues [34].
One sequence-based method for enumerating the abundance of
polyadenylated transcripts is SAGE [35]. As many lncRNAs
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25915themselves are polyadenylated, lncRNA transcript levels can be
deduced by way of direct enumeration of corresponding sequence
tags using SAGE technology. In fact, two antisense lncRNAs were
discovered using a SAGE-based method [25]. Since the invention
of SAGE technology in the mid 1990s, numerous SAGE libraries
representing a diversity of human and mouse, normal and
malignant tissues and cell lines have become publically available
[36]. Of the 755 human SAGE libraries in the Gene Expression
Omnibus (GEO) database, ,276 include SAGE libraries derived
from human cancers or dysplasias [37].
In this study, we compiled 272 human SAGE libraries to
delineate lncRNA transcription patterns across a broad spectrum
of human tissues and cancers. Using a custom lncRNA discovery
pipeline, we parsed over 24 million SAGE sequence tags to deduce
(1) the specific lncRNA expression patterns in 26 human tissues
and discovered ubiquitously expressed as well as tissue specific
lncRNAs, and (2) the aberrant expression patterns of lncRNAs in
19 human cancers.
Results
Assembling human SAGE libraries of normal and cancer
tissues
A total of 1,824 SAGE libraries (in short SAGE, long SAGE
and SAGE-seq format) of human and non-human origins are
publically available via GEO. To explore lncRNA expression in
the broadest range of human tissue types and cancer types, we
downloaded 360 GEO accessioned human short SAGE libraries
comprised of libraries curated by the Cancer Genome Anatomy
Project (324 libraries) and lung tissue and cancer datasets (36
libraries) (Table S1). Individual libraries were filtered for sequence
depth, retaining only those libraries with .50,000 raw tags, to
provide 272 SAGE libraries for analysis using our lncRNA
discovery pipeline (Table S2). The 272 SAGE libraries are
comprised of a total of 24,436,076 raw sequence tags with an
average raw tag count of 90,212 per library. Collectively, the
libraries spanned 26 normal human tissue types, including 19
human cancer types, and 9 tissue types derived from cell line
libraries (Figure 1, Table S3).
Long non-coding RNA discovery pipeline
To generate lncRNA expression profiles, we developed a
lncRNA discovery pipeline to map tag-to-lncRNA matches
(Figure 2). A SAGE tag expression matrix was constructed from
all unique tags (n=716,330) identified within the dataset of 272
libraries. Unigene mapped and unmapped SAGE tags
(n=269,785 and n=446,545, respectively) were separated into
distinct expression matrices which were subsequently filtered to
retain only those tags with at least 2 raw tag counts in 3 or more
SAGE libraries. Using SAGE Genie to assign gene identifiers to
the Unigene IDs, 263 of the 61,054 filtered tags with correspond-
ing Unigene IDs mapped to known lncRNAs, and 15,773 tags
either lacked gene names or had ambiguous annotations (e.g.
transcribed loci, cDNAs, hypothetical genes). Based on the
absence of confirmed association with known genes, these
15,773 tag-to-Unigene ID matches were considered as candidate
lncRNA tags.
The 15,773 Unigene tags with ambiguous gene identifiers were
combined with the 17,816 unmapped, filtered tags for a total of
33,589 SAGE tags with the potential to generate tag-to-lncRNA
matches. Using SeqMap, we mapped 7,040 of the 33,589 tags to
lncRNA sequences from the reference lncRNA list (Table S4). The
proportion of tag-to-lncRNA matches is consistent with the fact
that our reference list of 9,891 lncRNAs represents only a portion
of the estimated 23,000 lncRNAs in the genome [33]. The
remaining tags that do not map to lncRNAs from our reference list
may represent antisense transcripts to protein-coding genes or
other ncRNAs which were filtered.
Of the 7,040 lncRNA tag matches, 3,831 mapped in the
forward orientation, while 3,209 mapped in the reverse direction.
In SAGE, tags matching transcript in the forward orientation are
likely derived from that transcript, while tags matching in the
reverse orientation are not. This is true regardless of whether the
gene is normally transcribed from the plus or minus DNA strand.
In this study, we were interested in the expression profiles of a
curated set of lncRNAs, rather than novel gene discovery. As
reverse tag matches do not corroborate the expression of the
lncRNAs described herein, these tags were excluded from further
analysis.
The 3,831 tags newly mapped to lncRNAs were combined with
the 263 tags identified from Unigene mapping for a total of 4,094
tags uniquely mapping to lncRNAs. Where multiple tags mapped
to a distinct lncRNA, the tags were collapsed by summing the tag
counts to capture all transcript variants and isoforms. The end
result was a lncRNA expression matrix consisting of 2,649 distinct
lncRNAs (Tables S5 and S6). The lncRNAs with the highest
expression were detectable in the majority (.90%) of the 272
libraries (Table 1). These included characterized examples such as
nuclear paraspeckle assembly transcript 1 (NEAT1) and growth
arrest-specific 5 (GAS5).
Long non-coding RNA expression profiles in normal
human tissues
Of the 272 SAGE libraries, 72 represented normal human
tissues. Expression of lncRNAs was detected in all tissue types,
although the number of unique lncRNAs detected varied
considerably (Figure 3A). On average, there were 145 distinct
lncRNAs with a mean tags per million (TPM) of 20 detected in
each tissue. Tissues such as lymph node and gall bladder showed
the highest number of distinct lncRNAs, while the lowest numbers
of distinct lncRNAs were found in the muscle and liver.
Figure 1. Tissue-type distribution of the 272 SAGE libraries
with a minimum raw tag count of 50,000. (CL) indicates one SAGE
library that was generated from a mixture of human cell lines.
doi:10.1371/journal.pone.0025915.g001
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specific lncRNA expression profiles could be generated (Table S7).
Figure 4A shows the top 20 most highly expressed lncRNAs
detected in the panel of normal tissues. Distinct lncRNAs detected
at high expression levels in normal tissues included those
characterized in the literature such as NEAT1, GAS5 and X-
inactive-specific transcript (XIST). However, at least half of the
highly expressed lncRNAs are novel and currently uncharacter-
ized. To confirm the lncRNA expression profiles, we queried the
expression patterns of the most highly expressed lncRNAs using
RNASeq data from the Illumina Human BodyMap 2.0 project.
This data was recently added to Ensembl release 62 and is
presented as an optional track. Of our most highly expressed
lncRNAs, the majority were widely expressed in the tissue samples
from the Illumina dataset, consistent with our findings (Table S8,
Figures S1 and S2). Concurrently, lncRNA expression was also
found to be highly variable, with each human tissue having a
unique lncRNA expression pattern (Figure 4B). Intriguingly, a
number of lncRNAs were expressed in a tissue-exclusive manner
(Figure 3B).
Long non-coding RNA expression profiles in human
cancers
Aberrant protein-coding gene expression is well described in
cancer. However, aberrant expression of ncRNAs, including
miRNAs and lncRNAs, has only recently been associated with this
disease [2,26,27,38]. To delineate lncRNA expression profiles
associated with human cancers, we created a human cancer
expression matrix based on 167 cancer SAGE libraries included in
our dataset (Table S9). For the lung cancer dataset, metaplasia,
dysplasia and inflammatory tissues were excluded from analysis as
these represent precancerous stages [39,40]. Figure 5A shows the
top 20 most highly expressed lncRNAs across the profiled cancers.
Like the normal tissues, lncRNA expression in human cancer was
also found to be highly variable (Figure 5B).
Human cancers demonstrate significantly altered lncRNA
expression patterns
To determine the extent of differential lncRNA expression in
human cancer, we created three expression matrices for each
breast, brain and lung cancer which included a minimum of five
normal and five cancer SAGE libraries (Table S10). The breast,
brain and lung lncRNA expression matrices were independently
sorted for significant and differentially expressed lncRNAs (p-
Figure 2. LncRNA discovery pipeline using SAGE analysis.
Numbers indicate programs or filtering steps as follows: (1) filtering to
retain only those libraries with a minimum of 50,000 raw tag counts, (2)
identifying unique SAGE tags and constructing SAGE tag expression
matrix, (3) mapping SAGE tags to Unigene IDs using SAGE Genie
mapping files, (4) filtering lists to retain only tags with $2 raw counts in
a $3 of 272 libraries, (5) determining gene identity using SAGE Genie,
(6) separating Unigene tags mapping to lncRNAs and ambiguous
transcripts, (7) pooling ambiguous tags and unmapped tags, (8)
mapping sequence tags to the reference list of 9,891 lncRNAs using
SeqMap, a tag-to-gene mapping program, (remaining tags may map to
unannotated lncRNAs or antisense transcripts not included in our
reference list) (9) filtering tag matches for strand sense, (10) pooling
forward mapping tags and tags determined from Unigene, and (11)
confirming tag-to-lncRNA matches and summing tag counts for
lncRNAs with multiple tag matches. A complete list of lncRNAs
is provided as Table S5 and tag-to-lncRNA matches are provided as
Table S6.
doi:10.1371/journal.pone.0025915.g002
Table 1. The eleven most highly expressed lncRNAs detected
in .90% of the 272 SAGE libraries.
Gene Name Ensembl Gene Chr Start (bp) End (bp) Strand
MALAT1 ENSG00000251562 11 65265233 65273940 1
GAS5 ENSG00000234741 1 173833038 173838020 21
NEAT1 ENSG00000245532 11 65190245 65213011 1
NCRNA00188 ENSG00000175061 17 16342289 16367300 1
RP11-425M5.7 ENSG00000225759 20 36247700 36251521 21
SNHG6 ENSG00000245910 8 67833919 67838633 21
SNHG5 ENSG00000203875 6 86386725 86388451 21
SCAND2 ENSG00000176700 15 85174682 85185695 1
AC104759.1 ENSG00000246638 15 31685046 31696932 1
AC002472.9 ENSG00000230513 22 21356175 21364631 1
AC090937.2 ENSG00000225733 3 14961854 14989931 21
Also see Table S5.
doi:10.1371/journal.pone.0025915.t001
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parametric permutation test [41]). In each type of cancer, we
found at least 200 lncRNAs to have significant differential
expression based on these criteria (Figure 6A). Intriguingly, there
was overlap between the lncRNAs that were differentially
expressed in each tissue (Figure 6B), including 8 lncRNAs that
were differentially expressed in all three cancers (Table 2). The ten
most up- and down-regulated lncRNAs for each cancer are found
in Table S11.
Chromosomal distribution of long non-coding RNAs
We constructed a distribution plot to determine the chromo-
somal distribution of the 9,891 lncRNA genes in our lncRNA
reference list (Table S3). The lncRNAs are distributed throughout
the genome and are present on every chromosome (Figure 7).
Protein-coding genes and miRNAs appear to share a similar
chromosome distribution (Spearman correlation p.0.05, Figure
S3A). However, the chromosome distribution of lncRNAs did not
correlate with either protein-coding genes or miRNAs (Spearman
correlation p,0.05, Figures S3B, S3C).
Discussion
In recent years, the concept of the functional genome has been
re-written to include a multitude of newly discovered classes of
ncRNA transcripts [42,43,44,45]. Although the functional signif-
icance of long non-coding RNAs has long been recognized
[46,47], the abundance and scale of lncRNA expression changes
in cancer is just beginning to come to light. For this reason,
charting the transcriptional landscape of lncRNAs across human
tissue and cancer types is a key step in understanding lncRNA
functional significance in cancer.
Here, we present the first multi-tissue, cross-cancer lncRNA
expression profiling study. Large-scale expression profiling data-
sets, such as SAGE, represent a valuable resource for investigating
the expression pattern of polyadenylated lncRNAs. While this
approach excludes the profiling of non-polyadenylated lncRNAs,
it nonetheless facilitates the simultaneous profiling of thousands of
polyadenylated lncRNAs in a wide range of human tissues and
cancers. Using 272 SAGE libraries, representing 26 non-
malignant human tissues, 19 human cancer types and 9 cancer
cell lines, we have produced a first generation atlas of cross-cancer
lncRNA expression profiles as a resource for this fast growing area
of cancer research. Current estimates of the number of lncRNAs
encoded in the human genome vary widely, ranging from ,7,000
to 23,000 or more [7]. These estimates rival the abundance of the
estimated 20,000+ protein-coding genes. Our analysis showed that
lncRNAs are distributed on all 22 autosomes and sex chromo-
somes, yet the distribution pattern did not correlate with either
protein-coding genes or miRNAs (Figure 7, Figure S3).
Examination of 72 SAGE libraries of normal human tissues
revealed lncRNA expression in brain, breast, esophagus, gall
bladder, heart, liver, lung, lymph node, muscle, peritoneum,
placenta, prostate, retina, spinal cord, stomach, thyroid, vascular
tissue, embryonic stem cells and white blood cells. We find extensive
and highly differential patterns of lncRNA expression in normal
human tissues (Figures 3 and 4), corroborating a previous report of
tissue-specific ncRNA patterns [34]. For example, the lncRNA
NCRNA00116 was highly expressed in the contractile tissues,
namely heart (TPM=349) and muscle (TPM=399). LncRNAs
ENSG00000230658 and ENSG00000235621 showed very high
expression (TPM=888) in placenta and esophagus (TPM=820)
respectively, but low or undetectable expression in other tissues,
which may indicate a tissue-specific role for these transcripts. The
brain-associated and putative tumor suppressor lncRNA maternally
Figure 3. Distribution and levels of lncRNA expression in normal human tissues. (A) Number of distinct lncRNAs expressed in normal
human tissues, white blood cells and embryonic stem cells with a minimum average TPM of 20. The values in brackets indicate the number of SAGE
libraries for each tissue. (B) Examples of lncRNAs detected exclusively in a single normal human tissue or in embryonic stem cells (ESC) with a
minimum expression level of 10 TPM. For tissues with two or more libraries, the TPM values were averaged. LncRNAs without names are labeled with
an Ensembl ID.
doi:10.1371/journal.pone.0025915.g003
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in our dataset (TPM=677), but showed low level expression in
other tissue types (Figure 4). Collectively, these data suggest some
lncRNAs may function in a tissue-specific manner.
Only ,1% of the lncRNAs were ubiquitously expressed across
all tissues examined. These constantly expressed lncRNAs are
reminiscent of the expression patterns of ‘‘housekeeping’’ protein-
coding genes [49]. The eleven lncRNAs in Table 1 were expressed
Figure 4. Expression patterns of lncRNAs in normal human tissues. (A) LncRNAs with the highest overall expression (B) LncRNAs with the
highest variance by a coefficient of variation (CV) test. Heatmaps indicate the relative intensity (normalized TPM) of each lncRNA across seventeen
human tissues, white blood cells and human embryonic stem cells. Where more than one SAGE library was available, the TPM values were averaged.
For the heatmap, the maximum threshold was set at 300 TPM. LncRNAs without names are labeled with an Ensembl ID.
doi:10.1371/journal.pone.0025915.g004
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that these transcripts may participate in common biological
processes. However, the absolute expression level varied for each
tissue, sometimes by hundreds of TPM (Figure 4). This suggests
certain lncRNAs may be required at different cellular levels in
different tissues or under different conditions, much like many
constitutively expressed protein-coding genes [50,51,52]. The
concept of lncRNAs functioning as constitutively expressed
regulators has been previously proposed. For example, the
lncRNA XIST is critical for female development due to its
functional role in X-chromosome inactivation [47,53]. Concor-
dantly, a number of the most highly and frequently expressed
Figure 5. Expression patterns of lncRNAs in human cancers. (A) LncRNAs with the highest overall expression (B) LncRNAs with the highest
variance by a coefficient of variation (CV) test. Heatmaps indicate the relative intensity (normalized TPM) of each lncRNA across seventeen human
cancers and human embryonic stem cells. Where more than one SAGE library was available, the TPM values were averaged. For the heatmap, the
maximum threshold was set at 300 TPM. LncRNAs without names are labeled with an Ensembl ID.
doi:10.1371/journal.pone.0025915.g005
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processes, including NEAT1, a structural scaffold for paraspeckle
formation [14,54], MALAT1 which regulates alternative splicing
[31] and small nucleolar RNA host gene 6 (SNHG6) which hosts a
snoRNA, which function in RNA modification [55]. These
findings suggest that lncRNAs may be critical to normal tissue
maintenance and function.
In this cross-cancer type analysis, we found that lncRNAs
aberrantly expressed in a specific cancer may also be altered in
other cancers. For example, while MEG3 is highly expressed in
normal brain tissues, this lncRNA was strongly decreased in our
brain cancer datasets, and strikingly so in gall bladder, retinal and
prostate cancers, consistent with the proposed tumor suppressor
role for MEG3 [48,56,57]. In another example, miR155 host gene
(miR155HG), a lncRNA processed to the miRNA miR-155, was
highly overexpressed in B-cell lymphoma consistent with previous
reports [16], but also was also upregulated in esophageal and gall
bladder cancers.
Long non-coding RNAs are also implicated in the regulation of
embryogenesis [58,59,60]. Fetal lncRNAs reactivated in cancers
may represent critical regulators of pluripotency or cellular
growth. For example, the lncRNA urothelial cancer associated 1
(UCA1) has demonstrated roles in both embryonic development
and is implicated in bladder cancer, supporting this concept [61].
In our datasets, we found several lncRNAs with low expression in
normal tissues, but with high expression in both embryonic stem
cells and cancer (Table S12). While these reactivated fetal
lncRNAs represented mostly uncharacterized examples, H19,a
well-studied lncRNA with associations in both mammalian
development and cancer [53], was also detected in our dataset.
Interestingly, NEAT1, which is constitutively and highly expressed
in normal tissues [34,62], with the exception of embryonic stem
cells, was downregulated in lung, liver, esophageal and retinal
cancers (retinoblastoma).
Since genomic amplifications and deletions are key mechanisms of
gene deregulation in cancer, we investigated changes in lncRNA
expression in genomic regions frequently altered in breast, brain and
lung cancer. Comparison of the significantly (p,0.05) deregulated
lncRNAs common between brain, breast and lung cancer tissues
revealed eight lncRNAs were differentially regulated ($2-fold)
compared to normal tissue. Intriguingly, three of these lncRNAs -
ENSG00000226380, ENSG00000230937 and ENSG00000253288 -
were located on 7q32.3, 1q32.2, and 8q24.23, respectively, in regions
completely devoid of protein-coding genes. Like protein-coding genes
and miRNAs, it is possible that differential lncRNA expression is
driven by similar mechanisms of disruption, including copy number
gain/loss or aberrant methylation patterns. Indeed, high level
amplification of lncRNA containing loci such as cytoband 19p12
Figure 6. Aberrantly expressed lncRNAs in human cancers. (A) Number of lncRNAs showing significant expression changes. The number of
lncRNAs determined to have significant (BH p-value ,0.05) differential expression of 2-fold or greater reported. Solid bars indicate upregulated
genes, while bars with hatch marks indicate downregulated genes (B) Venn diagram of differentially expressed lncRNAs in human carcinomas.
doi:10.1371/journal.pone.0025915.g006
Table 2. Aberrantly expressed lncRNAs common to brain, breast and lung cancers.
Fold Change Corrected p-value
lncRNA Ensembl Gene ID Chr Start End Strand Brain Breast Lung Brain Breast Lung
AC058791.1 ENSG00000230937 7 130565751 130598069 21 7.00 23.00 3.59 0.00122 0.02373 0.00000
CTA-55I10.1 ENSG00000255717 1 209602165 209606183 1 3.37 22.05 2.72 0.00041 0.00190 0.00000
NCRNA00263 ENSG00000247556 10 102133372 102143125 1 12.37 2.10 2.46 0.00004 0.00056 0.00000
AC080037.2 ENSG00000245411 17 70594180 70636611 21 3.08 2.76 22.14 0.00009 0.00027 0.00141
AC012652.1 ENSG00000226380 15 41576203 41601901 1 6.45 3.53 22.33 0.00026 0.00018 0.03657
RP11-18C24.6 ENSG00000253288 12 120928131 120933743 21 22.48 23.13 22.86 0.00405 0.00639 0.01311
RP11-238K6.1 ENSG00000235823 8 138821687 139095813 21 7.07 4.18 24.35 0.00529 0.00012 0.00037
SNHG1 ENSG00000248008 11 62619460 62623386 21 3.04 3.27 25.03 0.00403 0.00043 0.00003
doi:10.1371/journal.pone.0025915.t002
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of 12p13.2 (which contains a number of lncRNA loci) has been
reported in breast cancer, glioblastoma, astrocytoma, and squamous
cell lung cancer [64,65,66,67]. Likewise, aberrant expression of a
number of lncRNAs has been tied to altered methylation patterns
[68,69]. However, the mechanism(s) driving aberrant lncRNA
expression remains mostly unknown.
While lncRNAs have been documented for nearly three
decades, the magnitude and diversity of lncRNA expression has
only recently been appreciated. It is estimated that lncRNAs in the
human genome number into the tens of thousands, effectively
doubling the number of potential gene targets in cancer gene
expression networks. Large scale, cross-tissue and cancer studies
are crucial to understanding the regulation of lncRNA expression
and how these novel transcripts integrate with our current
understanding of the mammalian transcriptome. Moreover, a
deeper understanding of lncRNA expression will not only expand
the number of potential target cancer genes, but also facilitate
development of novel anti-cancer therapies, such as gene
regulation mediated by antisense RNAs [70] or targeting
lncRNA-protein interactions [28].
Materials and Methods
SAGE Libraries
This study uses publically available SAGE libraries for data
analysis. A total of 360 SAGE libraries, including 324 from the
Cancer Genome Anatomy Project (CGAP) SAGE library
collection (GSE15309), 19 lung bronchial epithelium libraries
(GSE3707), 13 lung cancer libraries (GSE7898) and 4 never
smoker bronchial epithelium libraries (GSE5473), were down-
loaded from GEO (Table S1). Libraries constructed from non-
human samples, as well as long SAGE and SAGE-seq libraries
were not used in this study. To facilitate direct comparison the
SAGE libraries were filtered to retain only those libraries with
.50,000 raw tag counts resulting in 272 libraries suitable for
analysis (Table S2).
Long non-coding RNA reference list
The lncRNA discovery pipeline is based on a reference list of
human lncRNAs curated by the online genomic database Ensembl
release 62, built on the Genome Reference Consortium release
GRCh37 [71]. The lncRNA reference list was compiled from
1,239 Ensembl (v62) IDs designated as ‘lincRNAs’ (long intergenic
non-coding RNAs, a subclass of lncRNAs) and 8,652 Ensembl IDs
(v62) designated as ‘processed transcripts’ for a total of 9,891
lncRNAs (Table S4). All the lncRNAs used to query the SAGE
libraries were Ensembl curated transcripts without a predicted
open reading frame. The sequences of all lncRNA transcripts were
retrieved from Ensembl (v62) using the Biomart data management
system.
SAGE tag-to-gene mapping
Custom Perl scripts were used to create an expression matrix of
the unique SAGE tags across the 272 libraries (Perl scripts:
getuniquetags.pl and makeTable_April20.pl). The SAGE tags
were mapped to Unigene IDs using custom Perl scripts and a short
SAGE mapping file (mapping file: Hs_short) downloaded from
SAGE Genie (http://cgap.nci.nih.gov/SAGE), to create a matrix
of Unigene ID mapped tags and a matrix of unmapped tags (Perl
script: extractUnmappedTags_Unigene). The two expression
matrices of unmapped tags and Unigene mapped tags were
independently filtered to retain only tags with raw tag counts of 2
or more, appearing in at least 3 SAGE libraries.
For the Unigene mapped tags, gene identifiers were assigned to
Unigene IDs using SAGE Genie. From this dataset, tags matching
known or candidate lncRNAs were extracted manually. Candidate
lncRNAs are Unigene IDs with no gene name or matching one or
more of the following descriptors: ‘non-coding’, ‘non-protein’,
‘cDNA’, ‘transcribed locus’, ‘clone IMAGE’, ‘chr(#)orf(#)’,
‘hypothetical’, ‘family with sequence similarity’, ‘FLJ(#)’, or
‘KIAA(#)’. The candidate lncRNA tags were merged with the
unmapped tags and used as a single dataset from which to identify
sequence matches to the lncRNA reference list.
The tag-to-gene mapping program SeqMap was used to identify
perfect (0 mismatches) tag matches to the transcript sequences
from the reference lncRNA list. Tags mapping to lncRNAs were
filtered to retain those corresponding to the forward (‘sense’)
strand, while reverse tag matches do not corroborate the
expression of the candidate lncRNAs and were not analyzed
further. The forward strand tags that mapped to lncRNAs were
then combined with the Unigene tags that mapped to lncRNAs to
Figure 7. Chromosomal distribution of protein-coding genes, microRNAs and long non-coding RNAs in the human genome. Protein-
coding gene (n=20,655), microRNA (n=1,746) and long non-coding RNA (n=9,891) coordinates were downloaded from Ensembl v62 using BioMart.
doi:10.1371/journal.pone.0025915.g007
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This matrix was remapped to the lncRNA reference list to confirm
accurate tag-to-lncRNA matches.
Data pre-processing
In cases where multiple tags mapped to the same lncRNA, the
tags were compressed by summing the tag counts to capture all
lncRNA transcript variants and isoforms (Perl script: sumRows.pl).
SAGE tags mapping to more than one lncRNA were discarded.
Raw tag counts for each SAGE library were normalized to TPM to
facilitate adequate comparison among libraries. Additional expres-
sion matrices included only SAGE libraries of interest for a given
analysis, while removing any columns with unwanted SAGE
libraries. These submatrices were filtered to remove lncRNAs with
undetected expression. When a tissue or cancer was represented by
more than one SAGE library, the normalized TPM were averaged.
Finally,allEnsembl v62IDs were liftedto Ensembl v63,anymissing
or reassigned IDs were removed from the final lncRNA list.
Statistical analysis
To ensure statistical significance when comparing normal tissues
withcancerous tissues, the lncRNAexpression matrixwasfiltered to
retain only those tissues represented by a minimum of 5 normal and
5 cancer SAGE libraries. These SAGE libraries were used to derive
cancer specific expression matrices. To compare the expression of
lncRNAs between normal libraries and cancer libraries, we
performed a normalization of expression by permutation of SAGE
(NEPS) test as described [41]. LncRNAs with permutation scores of
.0.05wereconsidered tobe statistically significant.Allfoldchanges
were calculated by dividing the average expression of the cancer
SAGE libraries by the average expression of the normal SAGE
libraries. Variance calculations were performed by calculating the
coefficient of variation (CV) across the averaged normal or cancer
SAGE libraries. The lncRNA distribution plots were created by
normalizing the number of lncRNAs, miRNAs, or protein-coding
genes to 100 megabase (MB) of chromosome and then performing a
Spearman correlation.
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